Skip to main content

Table 1 Main characteristics of the studies included in the meta-analysis

From: The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis

Study

Author

Update year

Trial Phase

Capecitabine arm

Control arm

N (Capecitabine/ Control)

TNBC, N (X/Control)

Median follow-up (month)

Design

Setting

FinXX Trial

Joensuu

2017

III

DX + CEX

D + CEF

751/744

93/109

123.6

Addition

Adjuvant

GEICAM/2003–10

Martín

2015

III

ED-X

EC-D

715/669

95/71

79.2

Replace

Adjuvant

GAIN

V. Mo

2017

III

EC-PX

EPC

1511/1512

213/208

74

Replace

Adjuvant

US ncology 01062

O’Shaughnessy

2015

III

AC-DX

AC-D

1307/1304

396/384

60

Addition

Adjuvant

CREATE-X

Masuda

2017

III

X

None

443/444

139/147

43.2

Addition

Adjuvant

CIBOMA 2004/01

Lluch

2019

III

ED-X

EC-D

448/428

448/428

87.6

Addition

Neo/Adjuvant

Gepar TRIO

Minckwitz

2013

III

DAC-NX

DAC-DAC

301/321

NA

62

Replace

Neoadjuvant

CBCSG-010

Li

2019

III

DX-XEC

D-FEC

297/288

297/288

67

Addition

Adjuvant

CALGB49907

Muss

2019

III

X

CMF/AC

307/326

76/78

136.8

Replace

Adjuvant

  1. X capecitabine, C cyclophosphamide, M methotrexate, F 5-fluorouracil, A doxorubicin, E epirubicin, D docetaxel, BEV bevacizumab, P paclitaxel, N nab-paclitaxe, NA not available, N number